Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.52 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24490106 | 1.00 | KIF11 (0.52) | KIF11RYR2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL24490097 | 0.89 | SLC6A4 (0.62) | KIF11RYR2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL24490020 | 0.89 | SLC6A4 (0.62) | KIF11RYR2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL24490165 | 0.87 | KIF11 (0.55) | KIF11SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL22460956 | 0.81 | KIF11 (0.48) | KIF11SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL22460962 | 0.81 | KIF11 (0.48) | KIF11SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL22461269 | 0.81 | KIF11 (0.55) | KIF11SLC6A4SLC6A2SLC6A3ESR1 | |
| SCHEMBL22461271 | 0.81 | KIF11 (0.55) | KIF11SLC6A4SLC6A2SLC6A3ESR1 | |
| SCHEMBL24489998 | 0.81 | SLC6A2 (0.62) | KIF11RYR2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL22461555 | 0.81 | SLC6A2 (0.62) | KIF11RYR2SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086194-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Suvalent Therapeutics, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | KIF11 3058/4885RYR2 4865/4885SLC6A4 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.